Evidence map›Paper›PMID 42505120›Full record

ArticleJournal of virology2026

The human cytomegalovirus chemokine binding protein UL22A is necessary for efficient reactivation from latency in CD34

Rebekah L Turner, Nicole L Diggins, Luke Slind, Jennifer Mitchell, Andrew H Pham, Christopher J Parkins, Wilma Perez, Samuel Medica, Michael Denton, Takeshi F Andoh and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Rebekah L TurnerVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.ORCID 0000-0003-2516-0353
Nicole L DigginsVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.ORCID 0000-0001-8007-7865
Luke SlindVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Jennifer MitchellVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Andrew H PhamVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Christopher J ParkinsVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Wilma PerezVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Samuel MedicaVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Michael DentonVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Takeshi F AndohVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Gabriela M WebbDivision of Pathobiology and Immunology, Oregon National Primate Research Center, Beaverton, Oregon, USA.
Daniel Andrade-VeraVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Daniel N StreblowVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.ORCID 0000-0002-6828-2492
Patrizia CaposioVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.ORCID 0000-0001-7579-849X
Meaghan H HancockVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.ORCID 0000-0003-2945-0147

Funding

The Administrative CoreP01AI127335 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI Patrizia Caposio · 2017 to 2026
$24.6M
MOLECULAR ASPECTS OF CYTOMEGALOVIRUS LATENCYR01AI021640 · NIAID · UNIVERSITY OF GUELPH · PI Meaghan H Hancock · 1985 to 2026
$8.1M
Interdisciplinary Training in Microbial Pathogenesis and ImmunologyT32AI170496 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI Patrizia Caposio, Scott M Landfear · 2023 to 2026
$1.5M
National Institute of Allergy and Infectious Diseases P01AI127335National Institute of Allergy and Infectious Diseases R01AI21640NIAID NIH HHS P01 AI127335NIAID NIH HHS R01 AI021640NIAID NIH HHS T32 AI170496NIH HHS T32AI170496
6 · The paper itself

Abstract

Herpesviruses and poxviruses encode secreted chemokine binding proteins that prevent the interaction between chemokines and their cognate G protein-coupled receptors to alter chemotactic gradients and intracellular signaling pathways. Human cytomegalovirus (HCMV) encodes the secreted protein UL22A (formerly UL21.5), which is described as a CCL5 (RANTES) binding protein and requires sulfation at two tyrosine residues (Y65 and Y69) for efficient RANTES interaction. In this report, we show that the UL22A protein and the UL22A Y65 and Y69 residues are necessary for efficient HCMV reactivation from latency in CD34 IMPORTANCE: Human cytomegalovirus (HCMV) is a ubiquitous herpesvirus that infects 60%-90% of the population worldwide. In immunocompetent individuals, primary infection is asymptomatic and results in lifelong latent infection in CD34

Indexed as

CytomegalovirusCytomegalovirus InfectionsHematopoietic Stem CellsViral ProteinsVirus ActivationVirus LatencyAnimalsAntigens, CD34Chemokine CCL5ChemokinesHumansMiceAntigens, CD34Chemokine CCL5ChemokinesViral ProteinschemokineHCMVhematopoietic progenitor cellslatencytyrosine sulfationUL22A

Identifiers

PMID42505120
PMCPMC13483475

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.